Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California. Show more
Location: 650 Castro Street, Mountain View, CA, 94041, United States | Website: https://www.altoneuroscience.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
70.39M
52 Wk Range
$1.60 - $17.55
Previous Close
$2.58
Open
$2.58
Volume
69,332
Day Range
$2.50 - $2.66
Enterprise Value
-74.76M
Cash
160.8M
Avg Qtr Burn
-13.25M
Insider Ownership
7.48%
Institutional Own.
77.52%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ALTO-300 Details Major depressive disorder (MDD) | Phase 2b Data readout | |
ALTO-100 Details Bipolar depression | Phase 2b Data readout | |
ALTO-100 Details Major depressive disorder | Phase 2b Update | |
ALTO-203 Details Major depressive disorder | Phase 2 Data readout | |
ALTO-101 Details Cognitive Impairment Associated with Schizophrenia | Phase 2 Data readout |